Chondrosarcoma Market is segmented By Treatment Option (Surgery (Curative Treatment), Chemotherapy (Limited Efficacy), Radiotherapy (Resistance in Con....
Market Size in USD
CAGR6.8%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 6.8% |
Market Concentration | Medium |
Major Players | Inhibrx, Servier, Eli Lilly and Company, Pfizer, Novartis |
The chondrosarcoma market is estimated to be valued at USD 961.2 Mn in 2024 and is expected to reach USD 1,521.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031. While chondrosarcoma remains an extremely rare type of bone cancer, advancements are being made in developing effective targeted therapies and immunotherapies to treat the disease.